Efficacy and outcomes of bempedoic acid versus placebo in patients with hypercholesterolemia: an updated systematic review and meta-analysis of randomized controlled trials.

IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiovascular Endocrinology & Metabolism Pub Date : 2024-06-20 eCollection Date: 2024-09-01 DOI:10.1097/XCE.0000000000000302

Aman Goyal, Sangam Shah, Krishna Dahal, Mah I Kan Changez, Muhammad Daoud Tariq, Varisha Zuhair, Urooj Shamim, Haleema Qayyum Abbasi, Abhigan Babu Shrestha, Ranjit Sah, Amir Humza Sohail

{"title":"Efficacy and outcomes of bempedoic acid versus placebo in patients with hypercholesterolemia: an updated systematic review and meta-analysis of randomized controlled trials.","authors":"Aman Goyal, Sangam Shah, Krishna Dahal, Mah I Kan Changez, Muhammad Daoud Tariq, Varisha Zuhair, Urooj Shamim, Haleema Qayyum Abbasi, Abhigan Babu Shrestha, Ranjit Sah, Amir Humza Sohail","doi":"10.1097/XCE.0000000000000302","DOIUrl":null,"url":null,"abstract":"Introduction: Bempedoic acid (BA) has shown varied efficacy in managing hyperlipidemia. We conducted the most extensive up-to-date meta-analysis, the first to include recent studies by Nissen et al., which boast the largest sample size.Methods: Literature search was done on Medline, EMBASE, and Cochrane Library. The primary endpoint was a change in low-density lipoprotein-cholesterol (LDL-C) levels, while secondary endpoints encompassed changes in lipid parameters, clinical endpoints, and safety endpoints. The least-square mean (LSM) percent change was utilized for lipid changes, with statistical significance set at P < 0.05.Results: This analysis included 12 randomized control trials with 22,249 participants. BA exhibited a substantial reduction in LDL-C levels [LSM % change, -24.34; 95% confidence interval (CI), -27.80 to -20.88; P < 0.0001], total cholesterol levels (LSM % change, -16.62; 95% CI, -21.70 to -11.54; P < 0.00001) and high-density lipoprotein-cholesterol (HDL-C) levels (LSM % change, -4.22; 95% CI, -5.51 to -2.92; P < 0.00001) compared to the placebo.Conclusions: BA significantly lowers LDL-C, total cholesterol, HDL-C, non-HDL-C, high sensitivity C reactive protein, and apolipoprotein levels.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11191974/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Endocrinology & Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/XCE.0000000000000302","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Bempedoic acid (BA) has shown varied efficacy in managing hyperlipidemia. We conducted the most extensive up-to-date meta-analysis, the first to include recent studies by Nissen et al., which boast the largest sample size.

Methods: Literature search was done on Medline, EMBASE, and Cochrane Library. The primary endpoint was a change in low-density lipoprotein-cholesterol (LDL-C) levels, while secondary endpoints encompassed changes in lipid parameters, clinical endpoints, and safety endpoints. The least-square mean (LSM) percent change was utilized for lipid changes, with statistical significance set at P < 0.05.

Results: This analysis included 12 randomized control trials with 22,249 participants. BA exhibited a substantial reduction in LDL-C levels [LSM % change, -24.34; 95% confidence interval (CI), -27.80 to -20.88; P < 0.0001], total cholesterol levels (LSM % change, -16.62; 95% CI, -21.70 to -11.54; P < 0.00001) and high-density lipoprotein-cholesterol (HDL-C) levels (LSM % change, -4.22; 95% CI, -5.51 to -2.92; P < 0.00001) compared to the placebo.

Conclusions: BA significantly lowers LDL-C, total cholesterol, HDL-C, non-HDL-C, high sensitivity C reactive protein, and apolipoprotein levels.

查看原文本刊更多论文

贝母多酸与安慰剂对高胆固醇血症患者的疗效和结果：随机对照试验的最新系统回顾和荟萃分析。

简介：鱼腥草酸（BA）在控制高脂血症方面具有不同的疗效。我们进行了最广泛的最新荟萃分析，首次纳入了样本量最大的 Nissen 等人的最新研究：方法：我们在 Medline、EMBASE 和 Cochrane 图书馆进行了文献检索。主要终点是低密度脂蛋白胆固醇（LDL-C）水平的变化，次要终点包括血脂参数的变化、临床终点和安全性终点。血脂变化采用最小平方均值（LSM）百分比变化，统计显著性以 P 为标准：该分析包括 12 项随机对照试验，共有 22,249 人参与。BA 可显著降低 LDL-C 水平[LSM 百分比变化，-24.34；95% 置信区间 (CI)，-27.80 至 -20.88；P P P 结论：BA 可显著降低 LDL-C 水平：BA 能明显降低低密度脂蛋白胆固醇、总胆固醇、高密度脂蛋白胆固醇、非高密度脂蛋白胆固醇、高敏 C 反应蛋白和脂蛋白水平。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular Endocrinology & Metabolism CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

5.60

自引率

0.00%

发文量